Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
Key facts
- Who runs it
- Vivet Therapeutics SAS
- Where
- Ann Arbor, Dallas, New Haven, Orlando, Sacramento, and Winston-Salem, United StatesSee the 6 sitesAlso in 3 other countries, 4 sites
- Trial code
- NCT04537377
- EU 2023-509998-23-00
- EudraCT 2020-000963-22
- U1111-1301-8786
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 4 people enrolled
- Started
- 3 Sept 2021
- Expected to end
- 18 Jun 2029
- Type of study
- Interventional
- Treatments tested
- VTX-801
- Record updated
- 30 January 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Other criteria
- Main Inclusion Criteria:
- Male or female aged 18 and 65 years inclusive
- Confirmed diagnosis of WD
- Treated for WD according to international recommendations with no current evidence for inadequate treatment
- Stable WD for ≥ 1 year, defined as: (i) No significant change in neurologic examination and in status of mood disorder and (ii) Stable laboratory parameters used to assess copper metabolism; Main Exclusion Criteria:
- ALT level ≥ 2 ULN that is not readily explained by extrinsic factors
- Total bilirubin > 1.5 x ULN in the absence of proven Gilbert's syndrome; in case of Gilbert's syndrome, direct bilirubin > ULN
- INR > 1.2
- Any signs of liver cirrhosis decompensation, including gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrollment visit
- Patient has moderate or severe renal impairment defined as eGFR CKD-EPI < 60 mL/min/1.73 m2, or patient has nephritis or nephrotic syndrome
- Any history or current evidence of HIV-1, HIV-2, HTLV 1, or HTLV-2 infection
- Any history or current evidence of hepatitis B infection
- Any history of hepatitis C infection, unless previous viral RNA assays in two samples, collected at least 6 months apart, are negative
- Positive QuantiFERON®-TB Gold tuberculosis test result
- Any concomitant disorder/condition - including hepatic disorders - or treatment possibly interfering with the conduct or evaluation of the study
- Any history of diabetes
- Pregnancy or breastfeeding
- Body Mass Index ≥ 35 kg/m2; Other protocol defined Inclusion/ Exclusion criteria may apply
Where in United States
Also in 3 other countries, 4 sites
- University of Michigan Health SystemAnn Arbor, United States
- University of Texas Southwestern Medical CenterDallas, United States
- Yale University School of MedecineNew Haven, United States
- Advent HealthOrlando, United States
- UC Davis Medical CenterSacramento, United States
- Wake Forest School of MedicineWinston-Salem, United States
About the trial
What the trial wants to find out
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.
The group in the trial
- VTX-801Treatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease
- Record updated
- 30 January 2026